MRK ▲ +0.3% - Merck & Co., Inc.
$MRK Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 2b Study in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
30-SEP-2026 08:16 AM ET
Share this post
More filings for $MRK
MRK ▲ +0.3% - Merck & Co., Inc.Sep 30, 2026MRK ▲ +0.1% - Merck & Co., Inc.Sep 28, 2026MRK ▲ +0.4% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.4% - Merck & Co., Inc.Sep 25, 2026MRK ▲ +0.2% - Merck & Co., Inc.Sep 22, 2026MRK ▲ +0.0% - Merck & Co., Inc.Sep 21, 2026
View full $MRK filing history →💬 Comments
Loading comments…
Leave a comment